High-risk HPV DNA detected in less than 2% of over 25,000 cytology negative imaged liquid-based Pap test samples from women 30 and older

Gynecologic Oncology

Volumn 115, Issue 2, 2009, Pages 257-261

  Bansal, Mona ^a   Austin, R Marshall ^a   Zhao, Chengquan ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cost effect; Gynecologic cytology; HPV testing; Negative Pap

Indexed keywords

VIRUS DNA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER RISK; CHILD; COHORT ANALYSIS; DNA DETERMINATION; FEMALE; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; IMAGING SYSTEM; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; SCHOOL CHILD; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

ADULT; AGE FACTORS; COHORT STUDIES; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL DISEASES; VAGINAL SMEARS;

EID: 70349731470     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.07.010     Document Type: Article

References (68)

1. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121 (2007) 621-632
2. Bosch F.X., Lorincz A., Muñoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55 (2002) 244-265
3. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2 (2002) 342-350
4. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 (1999) 12-19
5. U.S. Food and Drug Administration. FDA News: FDA approves expanded use of HPV test. Available at http://www.fda.gov/bbs/topics/NEWS/2003/NEW00890.html. Accessed February 5, 2007.
6. Saslow D., Runowicz C.D., Solomon D., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J. Clin. 52 (2002) 342-362
7. Cervical Cytology Screening. ACOG Practice Bulletin No. 45. American College of Obstetricians and Gynecologists. Obstet.Gynecol. 102 (2003) 417-427
8. Rodriguez A.C., Burk R., Herrero R., et al. The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life. Sex Trans. Dis. 34 (2007) 494-502
9. Castle P.E., Schiffman M., Herrero R., et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacoste, Costa Rica. J. Infect. Dis. 11 (2005) 1808-1816
10. Clifford G.M., Gallus S., Herrero R., Muñoz N., Snijders P.J., Vaccarella S., et al., IARC HPV Prevalence Surveys Study Group. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366 (2005) 991-998
11. de Sanjosé S., Diaz M., Castellsagué X., Clifford G., Bruni L., Muñoz N., and Bosch F.X. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Inf. Dis. 7 (2007) 453-459
12. Datta S.D., Koutsky L.A., Ratelle S., Unger E.R., Shlay J., McClain T., et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann. Intern. Med. 148 (2008) 493-500
13. Cuzick J., Mayrand M.H., Ronco G., et al. New dimensions in cervical cancer screening. Vaccine 24S3 (2006) S390-S397
14. Cuzick J., Clavel C., Petry K.U., et al. Overview of North American Studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119 (2006) 1095-1101
15. Kitchener H.C., Almonte M., Thomson C., et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 10 7 (2009) 672-682
16. Bidus M.A., Maxwell G.L., Kulasingam S., et al. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. Obstet. Gynecol. 107 (2006) 997-1005
17. Maxwell G.L., Carlson J.W., Ochoa M., Krivak T., Rose G.S., and Myers E.R. Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries. Obstet. Gynecol. 100 (2002) 740-748
18. Kulasingam S.L., Hughes J.P., Kiviat N.B., et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288 (2002) 1749-1757
19. Kim J.J., Wright T.C., and Goldie S.J. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 287 (2002) 2382-2390
20. Goldie S.J., Kim J.J., and Wright T.C. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet. Gynecol. 103 (2004) 619-631
21. Kulasingam S.L., and Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290 (2003) 781-789
22. Goldhaber-Fiebert J.D., Stout N.K., Salomon J.A., et al. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J. Natl. Cancer Inst. 100 (2008) 308-320
23. Dawson A.E. Can we change the way we screen? The ThinPrep Imaging System: clinical trial data and early experience. Cancer Cytopathol. 102 (2004) 340-344
24. Dziura B., Quinn S., and Richard K. Performance of an imaging system vs. manual screening in the detection of squamous intraepithelial lesions of the cervix. Acta Cytol. 50 (2006) 309-311
25. Lozano R. Comparison of computer-assisted and manual screening of cervical cytology. Gynecol. Oncol. 104 (2007) 134-138
26. Davey E., d'Assuncao J., Irwig L., et al. Accuracy of reading liquid-based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study. BMJ 335 (2007) 31-35
27. Zhao C., Florea A., Onisko A., and Austin R.M. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods. Gynecol. Oncol. 114 (2009) 383-389
28. Berstein S.J., Sanchez-Ramos L., and Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am. J. Obstet. Gynecol. 185 (2001) 308-317
29. Abulafia O., Pezzullo J.C., and Shere D.M. Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: a quantitative survey. Gynecol. Oncol. 90 (2003) 137-144
30. Ferreccio C., Bratti M.C., Sherman M.E., et al. A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. Ca Epid. Biom. Prev. 12 (2003) 815-823
31. Beerman H., van Dorst E.B., Kuenen-Boumeester V., and Hogendoorn P.C. Superior performance of liquid-based versus conventional cytology in a population-based cervical cancer screening program. Gynecol. Oncol. 112 (2009) 572-576
32. U. S. Census Bureau American Community Survey (ACS); http://www.census.gov/acs/www/ Last accessed June 23, 2009.
33. Bandyopadhyay S., Austin R.M., Dabbs D., and Zhao C. Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test results. Arch. Pathol. Lab. Med. 132 (2008) 1874-1881
34. Zhao C., and Austin R.M. Human papillomavirus DNA detection in ThinPrep Pap test vials is independent of cytologic sampling of the transformation zone. Gynecol. Oncol. 107 (2007) 231-235
35. Zhao C., and Austin R.M. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample. Cancer Cytopathol. 114 (2008) 242-248
36. Castle P.E., Lorincz A.T., Scott D.R., et al. Comparison between prototype hybrid capture and hybrid capture 2 human papillomavirus DNA assays for detection of high grade cervical intraepithelial neoplasia and cancer. J. Clin. Microbiol. 41 (2003) 4022-4030
37. Cibas E.S., Hong X., Crum C.P., and Feldman S. Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples. Gynecol. Oncol. 104 (2007) 702-706
38. Zhao C., Elishaev E., Yuan K.H., Yu J., and Austin R.M. Very low human papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests. Cancer 111 5 (2007) 292-297
39. Herrero R., Hildesheim A., Bratti C., et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J. Natl. Cancer Inst. 92 (2000) 464-474
40. Hopman E.H., Rozendaal L., Voorhorst F.J., Walboomers J.M., Kenemans P., and Helmerhorst T.J. High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. Br. J. Obstet. Gynecol. 107 (2000) 600-604
41. Jacobs M., WalBoomers J., Snijders P., et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int. J. Cancer 87 (2000) 221-227
42. Sellors J.W., Mahony J.B., Kaczorowski J., et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. CMAJ 163 (2000) 503-508
43. Clavel C., Masure M., Bory J.P., et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br. J. Cancer 89 12 (2001) 1616-1623
44. Lazcano-Ponce E., Herrero R., Munoz N., et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int. J. Cancer 91 (2001) 412-420
45. Zuna R.E., Moore W., and Dunn S.T. HPV DNA testing of the residual sample of liquid-based Pap test: utility as a quality assurance monitor. Mod. Pathol. 14 3 (2001) 147-151
46. Molano M., Posso H., Weiderpass E., et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br. J. Cancer 87 (2002) 324-333
47. Petry K.U., Menton S., Menton M., et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br. J. Cancer 88 (2003) 1570-1577
48. Arora R., Kumar A., Prusty B.K., Kailash U., Batra S., and Das B.C. Prevalence of high-risk human papillomavirus (HR-HPV) types 16 and 18 in healthy women with cytologically negative Pap smear. Eur. J. Obstet. Gynecol. Reprod. Biol. 121 (2005) 104-109
49. Hoyer H., Scheungraber C., Kuehne-Heid R., et al. Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting. Int. J. Cancer 116 (2005) 136-143
50. Evans M.F., Adamson C.S.C., Papillo J.L., St. John T.L., Leiman G., and Cooper K. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer 106 (2006) 1054-1064
51. De Sanjose S., Almirall R., Lloveras B., et al. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm. Dis. 30 (2003) 788-793
52. Gupta S., Sodhani P., Sharma A., et al. Prevalence of high-risk human papillomavirus type 16/18 infection among women with normal cytology: risk factor analysis and implications for screening and prophylaxis. Cytopath. 20 (2009) 249-255
53. Rubio C.A. A trap for atypical cells. Am. J. Obstet. Gynecol. 128 (1977) 687-688
54. Lorincz A.T., and Richart R.M. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch. Path. Lab. Med. 127 (2003) 959-968
55. Mandelblatt J.S., Lawrence W.F., Womack S.M., et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287 (2002) 2372-2381 Comment in: JAMA. 2002; 287: 2428-2429
56. Gemmen K., Blackburne R.E., van Engen A.K., and Partlow K.L. A health economic model to determine the cost-effectiveness of cervical cancer screening methods. J. Lower Gen. Tract. Dis. 197A (2006) 10
57. Sherman M.E., Lorincz A.T., Scott D.R., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J. Natl. Cancer Inst. 95 (2003) 46-52
58. Castle P.E., Wacholder S., Lorincz A.T., et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J. Natl. Cancer Inst. 94 (2002) 1406-1414
59. Castle P.E., Wacholder S., Sherman M.E., et al. Absolute risk of subsequent abnormal Pap among oncogenic human papillomavirus DNA-positive cytologically negative women. Cancer 95 (2002) 2145-2151
60. Sherman M.E., Lorincz A.T., Scott D.R., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. JNCI 95 (2003) 46-52
61. Khan M.J., Castle P.E., Lorincz A.T., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97 (2005) 1072-1079
62. Miller A.B. The (in)efficiency of cervical screening in Europe. Eur. J. Cancer 38 (2002) 321-326
63. Naucler P., Ryd W., Tornberg S., et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J. Natl. Cancer Inst. 101 (2009) 88-99
64. Kjaer S., Hogdall E., Frederiksen K., et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 66 (2006) 10630-10636
65. Castle P.E., Fetterman B., Poitras N., et al. Five-year experience of human papillomavirus DNA and Papanicolaou test co-testing. Obstet. Gynecol. 113 (2009) 595-600
66. Jastania R., Geddie W.R., Chapman W., et al. Chracteristics of apparently false-negative digene hybrid capture 2 high risk HPV DNA testing. Am. J. Clin. Pathol. 125 (2006) 223-228
67. Stoler M., Castle P.E., Solomon D., and Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am. J. Clin. Pathol. 127 (2007) 335-337
68. Zhao C., and Austin R.M. Follow-up outcomes of cytological and histological abnormalities among women with negative computer-imaged liquid-based Pap and positive HPV DNA test results. Mod. Path. 22S (2009) 99A